KRATON RECEIVES ISCC PLUS CERTIFICATION FOR ITS NIORT MANUFACTURING FACILITY
THE WOODLANDS, Texas, March 27, 2025 /PRNewswire/ -- Kraton Corporation, a leading global producer of specialty polymers and high-value biobased products derived from by-products of pine wood pulping, is pleased to announce its manufacturing facility in Niort, France, has received an International Sustainability and Carbon Certification (ISCC) PLUS certification. The certification enables Kraton to offer 100% ISCC PLUS certified AMS and AMS Phenolics resins through a mass balance attribution method.
"Our SYLVARES™ and SYLVATRAXX™ brands feature a range of high-performance AMS and AMS Phenolics resins used in specialty adhesives and tire applications", said Lana Culbert, Kraton Pine Chemicals VP of Marketing. "Our ISCC PLUS journey began in 2021 with the certification of our Sandarne, Sweden facility. Earning this certification for our Niort plant marks a significant milestone, further expanding our portfolio of sustainable solutions."
The certification of the Niort facility reinforces Kraton's commitment to advancing the biobased and circular economy. By enabling customers to integrate more sustainable materials into their supply chains, Kraton remains at the forefront of sustainable innovations, dedicated to reducing carbon emissions and driving the transition toward a more sustainable future.
The International Sustainability and Carbon Certification (ISCC) is an independent, multi-stakeholder initiative and a leading certification system that ensures proper mass-balancing bookkeeping and reporting of recycled and renewable-based materials across the supply chain.
For more information about Kraton, please visit www.KRATON.com.
About Kraton CorporationKraton Corporation is a leading global producer of specialty polymers and high-value performance products derived from renewable resources. Kraton's polymers are used in a wide range of applications, including adhesives, coatings, consumer and personal care products, sealants, and lubricants, and medical, packaging, automotive, paving and roofing products. As the largest global provider in the pine chemicals industry, the company's pine-based specialty products are sold into adhesive, road and construction and tire markets, and it produces and sells a broad range of performance chemicals into markets that include fuel additives, oilfield chemicals, coatings, metalworking fluids and lubricants, inks, and mining. Kraton offers its products to a diverse customer base in over 70 countries worldwide.
*Kraton, the Kraton logo and design are all trademarks of Kraton Corporation, or its subsidiaries or affiliates, in one or more, but not all countries.
Media Contact: Mariam Stevens: (346) 435-8042
View original content to download multimedia:https://www.prnewswire.com/news-releases/kraton-receives-iscc-plus-certification-for-its-niort-manufacturing-facility-302412323.html
SOURCE Kraton Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
At €41.86, Is Arcadis NV (AMS:ARCAD) Worth Looking At Closely?
Arcadis NV (AMS:ARCAD), might not be a large cap stock, but it saw significant share price movement during recent months on the ENXTAM, rising to highs of €48.96 and falling to the lows of €39.60. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Arcadis' current trading price of €41.86 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Arcadis's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 15.48x is currently trading slightly below its industry peers' ratio of 15.57x, which means if you buy Arcadis today, you'd be paying a reasonable price for it. And if you believe Arcadis should be trading in this range, then there isn't much room for the share price to grow beyond the levels of other industry peers over the long-term. In addition to this, it seems like Arcadis's share price is quite stable, which could mean there may be less chances to buy low in the future now that it's trading around the price multiples of other industry peers. This is because the stock is less volatile than the wider market given its low beta. Check out our latest analysis for Arcadis Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Arcadis' earnings over the next few years are expected to increase by 54%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? ARCAD's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at ARCAD? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio? Are you a potential investor? If you've been keeping an eye on ARCAD, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for ARCAD, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Case in point: We've spotted 1 warning sign for Arcadis you should be aware of. If you are no longer interested in Arcadis, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Koninklijke Heijmans N.V. (AMS:HEIJM) surges 3.9%; individual investors who own 56% shares profited along with institutions
Koninklijke Heijmans' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 25 shareholders own 42% of the company Institutions own 30% of Koninklijke Heijmans Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. A look at the shareholders of Koninklijke Heijmans N.V. (AMS:HEIJM) can tell us which group is most powerful. With 56% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Individual investors gained the most after market cap touched €1.5b last week, while institutions who own 30% also benefitted. Let's take a closer look to see what the different types of shareholders can tell us about Koninklijke Heijmans. See our latest analysis for Koninklijke Heijmans Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that Koninklijke Heijmans does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Koninklijke Heijmans' earnings history below. Of course, the future is what really matters. Hedge funds don't have many shares in Koninklijke Heijmans. JP Morgan Asset Management is currently the company's largest shareholder with 9.5% of shares outstanding. Waterbird B.V. is the second largest shareholder owning 8.4% of common stock, and C. Oomen holds about 5.1% of the company stock. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. We can see that insiders own shares in Koninklijke Heijmans N.V.. The insiders have a meaningful stake worth €82m. Most would see this as a real positive. It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently. The general public -- including retail investors -- own 56% of Koninklijke Heijmans. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability. It seems that Private Companies own 8.4%, of the Koninklijke Heijmans stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. While it is well worth considering the different groups that own a company, there are other factors that are even more important. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
9 hours ago
- Yahoo
Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®
Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0 Integration REDDING, Calif., June 29, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Medical Device Contract Manufacturing Market Size, Share, Forecast, & Trends Analysis by Device (Biochemistry, Immunoassay, CT, MRI, X-ray, Ultrasound, Pacemaker, Defibrillator, Oximeter) Services (Development, Manufacturing, QA) – Global Forecast to 2032", the Medical Device Contract Manufacturing market is projected to reach $171.19 billion by 2032, up from an estimated $84.8 billion in 2025, growing at a robust CAGR of 9.9% during the forecast period. The growth of the medical device contract manufacturing market is driven by increasing preference for outsourcing design, development, and manufacturing in the MedTech sector amid rising regulatory complexity and cost optimization needs. The market's expansion is fueled by advanced manufacturing technologies, changing regulatory landscapes requiring specialized expertise, Industry 4.0 adoption, and growing healthcare expenditure across key global markets. The industry is experiencing revolutionary transformation through sophisticated automation integration, AI and robotics adoption, and development of specialized regulatory compliance solutions. Leading companies are embracing digital manufacturing technologies while expanding into emerging markets and developing innovative value-added services for medical device manufacturers worldwide. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Specialized Manufacturing Excellence The medical device contract manufacturing market represents a paradigm shift in healthcare technology production and regulatory compliance optimization. As medical device companies increasingly prioritize core competencies like research and development while seeking specialized manufacturing expertise, contract manufacturing offers a revolutionary solution that addresses the growing demand for cost-effective, regulatory-compliant, and technologically advanced medical device production. Market leaders are investing heavily in advanced automation technologies and regulatory expertise, establishing manufacturing capabilities that can deliver scalable, compliant medical device solutions. This technological advancement is making sophisticated medical device manufacturing increasingly accessible while delivering superior quality and regulatory compliance benefits. Dynamic Growth Across Key Market Segments Based on device type, the IVD Devices segment dominates the market in 2025, capturing approximately 21% of the total market share due to high burden of chronic and infectious diseases propelling R&D in IVD, high preference for outsourcing immunoassay analyzer development, and growing demand for automated ELISA platforms. However, the Drug Delivery Devices segment is experiencing the fastest growth with 11.2% CAGR, driven by rising chronic disease incidence, growing adoption of biologic drugs, and trend toward self-administration of medications. Based on risk classification, the Moderate-risk Medical Devices segment leads the market, reflecting feasible outsourcing opportunities with careful regulatory compliance, frequent utilization of devices like syringes and catheters, and growing adoption in home healthcare settings. This segment is also anticipated to record the highest growth rate during the forecast period. Based on services, the Design & Development segment accounts for approximately 24% of the market in 2025, attributed to growing demand for advanced medical devices, high costs associated with device development, and increasing trend toward outsourcing technical expertise. This segment is also expected to register the highest CAGR of 11.7% during the forecast period. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through Industry 4.0 technology integration, emerging market expansion, and development of specialized regulatory compliance services. Companies are discovering new revenue streams through advanced automation capabilities and vertical supply chain integration while establishing comprehensive medical device manufacturing ecosystems. Key market drivers include: Outsourcing Preference Growth: Increasing trend toward outsourcing design, development, and manufacturing enabling medical device companies to focus on core competencies while reducing costs and time-to-market Advanced Manufacturing Technologies: Integration of AI, robotics, additive manufacturing, and IoT solutions enhancing efficiency, precision, and customization capabilities in medical device production Regulatory Landscape Evolution: Changing regulatory requirements compelling companies to seek specialized regulatory expertise and compliance services from experienced contract manufacturers Industry 4.0 Integration: Adoption of digital technologies, smart manufacturing systems, and blockchain-enabled traceability improving operational efficiency and regulatory compliance Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025 with approximately 44% of the global market, driven by well-developed manufacturing infrastructure, presence of leading contract manufacturers, high adoption of advanced manufacturing technologies, and strong academia-industry collaboration fostering technological capabilities. Asia-Pacific emerges as the fastest-growing region with a projected CAGR of 11.9% during 2025-2032, propelled by availability of skilled labor at competitive costs, rising quality standards in manufacturing, government initiatives for local medical device production, and good accessibility to cheaper raw materials. Europe represents a significant market, supported by stringent regulatory frameworks, advanced manufacturing capabilities, growing demand for specialized medical devices, and presence of leading contract manufacturing providers with emphasis on quality and compliance. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global medical device contract manufacturing market features an innovative competitive ecosystem comprising specialized contract manufacturers, electronics manufacturing services providers, and integrated healthcare technology companies. This diverse landscape fosters rapid technological advancement through sophisticated automation integration and specialized regulatory expertise development. Industry leaders are implementing integrated solutions that combine advanced manufacturing technologies with comprehensive regulatory services and quality assurance capabilities. Companies are pursuing strategic mergers and acquisitions while addressing scalability and compliance challenges across different medical device segments. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global medical device contract manufacturing market include Jabil Inc. (U.S.), Gerresheimer AG (Germany), Nordson Corporation (U.S.), Teleflex Incorporated (U.S.), Celestica Inc. (Canada), Plexus Corp (U.S.), SteriPack Group Ltd (U.S.), Nortech Systems, Inc. (U.S.), Invetech Pty. Ltd. (Australia), Flextronics International, LTD. (Singapore), Benchmark Electronics Inc. (U.S.), Integer Holdings Corporation (U.S.), and STRATEC SE (Germany). These companies are focusing on strategies such as advanced automation technology integration, specialized regulatory expertise development, comprehensive service portfolio expansion, strategic mergers and acquisitions, and geographic expansion into emerging markets to strengthen their market position. Latest Industry Developments Recent market developments include: Strategic CDMO Partnerships: Formation of Contract Development and Manufacturing Organization partnerships for specialized immunoassay systems and cartridge-based reagent manufacturing enhancing market capabilities Advanced Automation Integration: Implementation of AI and robotics technologies improving manufacturing efficiency, precision, and scalability while reducing time-to-market for medical devices Vertical Integration Initiatives: Strategic acquisitions enabling companies to optimize supply chains, enhance core capabilities, and diversify service offerings across the medical device value chain Market Challenges and Opportunities While the market shows strong growth potential, it faces challenges including complex regulatory compliance requirements across different jurisdictions, intellectual property protection concerns for high-risk devices, maintaining quality standards while reducing costs, and technical complexity in advanced medical device manufacturing. However, significant opportunities exist in expanding Industry 4.0 technology adoption, growing healthcare expenditure in developing countries, increasing demand for personalized medical devices, emerging applications in digital health and connected medical devices, and rising need for specialized manufacturing expertise in complex therapeutic areas. The Mid-scale Medical Device Companies segment is projected to experience rapid growth during the forecast period, driven by increasing focus on innovation and product introduction while adhering to cost constraints, competitive pressures requiring advanced manufacturing capabilities, and partnerships with contract manufacturers to offer high-quality products at competitive prices. Related Reports: Pharmaceutical Contract Development and Manufacturing Market Pharmaceutical Contract Packaging Market by Size, Share, Forecasts, & Trends Analysis IVD Contract Manufacturing Services Market by Size, Share, Forecasts IVD Assay Development Market Size, Share, Growth Analysis 2031 About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal Bombe Meticulous Market Research Pvt. Ltd. 1267 Willis St, Ste 200 Redding, California, 96001, U.S. USA: +1-646-781-8004 Europe: +44-203-868-8738 APAC: +91 744-7780008 Email- sales@ Visit Our Website: Connect with us on LinkedIn- Content Source: Logo - View original content to download multimedia: SOURCE Meticulous Market Research Private Limited Sign in to access your portfolio
